Cargando…

Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting

BACKGROUND: The aims of this study were to determine whether the quantitative HER2 gene amplification level is related to the key clinicopathological features that represent the aggressiveness of breast cancer (BC) and to determine whether the quantitative HER2 gene amplification level could predict...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ziping, Xu, Shuguang, Zhou, Liheng, Yin, Wenjin, Lin, Yanpin, Du, Yueyao, Wang, Yaohui, Jiang, Yiwei, Yin, Kai, Zhang, Jie, Lu, Jinsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818868/ https://www.ncbi.nlm.nih.gov/pubmed/29497312 http://dx.doi.org/10.2147/OTT.S157634

Ejemplares similares

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
por: Zhou, Liheng, et al.
Publicado: (2017)

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting
por: Wu, Ziping, et al.
Publicado: (2019)

Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
por: Wu, Ziping, et al.
Publicado: (2019)

Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy
por: Zhang, Shan, et al.
Publicado: (2020)

The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients
por: Sun, Lu, et al.
Publicado: (2020)

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du, Yueyao, et al.
Publicado: (2018)

Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
por: Bayarmaa, Battseren, et al.
Publicado: (2019)

Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer
por: Wang, Yaohui, et al.
Publicado: (2018)

Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy
por: Sha, Rui, et al.
Publicado: (2021)

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
por: Xu, Yaqian, et al.
Publicado: (2020)

Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials
por: Xu, Yaqian, et al.
Publicado: (2021)

Genetic polymorphisms of GGT1 gene (rs8135987, rs5751901 and rs2017869) are associated with neoadjuvant chemotherapy efficacy and toxicities in breast cancer patients
por: Sun, Lu, et al.
Publicado: (2023)

For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
por: Zhou, Qiong, et al.
Publicado: (2014)

Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
por: Wan, Caifeng, et al.
Publicado: (2023)

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis
por: Jiang, Yiwei, et al.
Publicado: (2012)

Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes
por: Yin, Kai, et al.
Publicado: (2015)

LncRNA MIR205HG expression predicts efficacy of neoadjuvant chemotherapy for patients with locally advanced breast cancer
por: Xu, Yaqian, et al.
Publicado: (2021)

MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells
por: Yin, Kai, et al.
Publicado: (2016)

HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer
por: Dai, Huijuan, et al.
Publicado: (2021)

Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study
por: Zhou, Qiong, et al.
Publicado: (2016)

LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication
por: Sheng, Xiaonan, et al.
Publicado: (2021)

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
por: Yin, Wenjin, et al.
Publicado: (2011)

SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer
por: Zhang, Lei, et al.
Publicado: (2020)

Upregulation of microRNA-1 inhibits proliferation and metastasis of breast cancer
por: Peng, Jing, et al.
Publicado: (2020)

Postoperative Fever: The Potential Relationship with Prognosis in Node Negative Breast Cancer Patients
por: Yan, Tingting, et al.
Publicado: (2010)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics
por: Peng, Jing, et al.
Publicado: (2017)

Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer–The EARLY-MYO-BC study
por: Chai, Yezi, et al.
Publicado: (2023)

HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
por: Gonullu, Burak, et al.
Publicado: (2023)

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
por: Li, Cunfu, et al.
Publicado: (2017)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

Raman Nanotags‐Guided Intraoperative Sentinel Lymph Nodes Precise Location with Minimal Invasion
por: Deng, Binge, et al.
Publicado: (2021)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

The clinical significance of HER2 protein amplification/expression in urinary bladder lesion
por: Hammam, Olfat, et al.
Publicado: (2015)

Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma
por: Muhetaer, Aishanjiang, et al.
Publicado: (2020)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014)

Added Value of HER-2 Amplification Testing by Multiplex Ligation-Dependent Probe Amplification in Invasive Breast Cancer
por: Kuijpers, Chantal C. H. J., et al.
Publicado: (2013)

HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours
por: Brożek, Izabela, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6n2cncqa69sokmm8jc2mhfu7ug